ACA
ITCI

American Capital Advisory’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

American Capital Advisory’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$132 – 1015
2025
Q1 		$132 Buy
+1
New +$125 ﹤0.01% 774

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

American Capital Advisory's ITCI Position: Q2 2025 in Review

American Capital Advisory sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1 share — an estimated $132 sold.

American Capital Advisory first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $132 in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • American Capital Advisory reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • American Capital Advisory sold 1 Intra-Cellular Therapies Inc. share in Q2 2025, an estimated $132.
  • American Capital Advisory first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
  • American Capital Advisory's Intra-Cellular Therapies Inc. position peaked at $132 in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on American Capital Advisory's 13F filing for Q2 2025, filed 5 Aug 2025.